Clinical Research Unit for Snake Bite, Rangoon, Burma.
Southeast Asian J Trop Med Public Health. 1989 Jun;20(2):271-7.
A controlled clinical trial of low-dose heparin was carried out in confirmed cases of Russell's viper bite. Twenty-eight patients with coagulable blood and serum FDP levels (more than 80 micrograms/ml) were included in the study. They were randomised to receive low-dose heparin in an initial dose of 50 units/kg body weight intravenously immediately after antivenom followed by a continuous infusion of 10 units/kg/hr in isotonic saline for 24 hours, or antivenom alone. Response to treatment was assessed clinically as well as by serial measurements of coagulation factors and biochemical variables. No features of systemic envenoming developed in any patient after treatment, but one patient in each group developed microscopic haematuria. No systemic bleeding or acute renal failure occurred in any patient. Recovery rate from the clotting defect was similar in the two groups, but in patients with initially very low fibrinogen levels there was a tendency for the heparin to restore fibrinogen faster than in comparable patients who did not receive heparin.
在确诊的罗素蝰蛇咬伤病例中进行了一项低剂量肝素的对照临床试验。28例血液可凝固且血清纤维蛋白降解产物水平(超过80微克/毫升)的患者纳入该研究。他们被随机分为两组,一组在注射抗蛇毒血清后立即静脉注射初始剂量为50单位/千克体重的低剂量肝素,随后以10单位/千克/小时的速度在等渗盐水中持续输注24小时;另一组仅接受抗蛇毒血清治疗。通过临床评估以及对凝血因子和生化变量的系列测量来评估治疗反应。治疗后任何患者均未出现全身中毒症状,但每组各有1例患者出现镜下血尿。任何患者均未发生全身出血或急性肾衰竭。两组从凝血缺陷中的恢复率相似,但在初始纤维蛋白原水平极低的患者中,肝素使纤维蛋白原恢复的速度比未接受肝素的类似患者更快。